Trial of a Novel Oral Cannabinoid Formulation in Patients with Hypertension: A Double-Blind, Placebo-Controlled Pharmacogenetic Study

Cannabidiol (CBD) is a non-psychoactive cannabinoid, and available evidence suggests potential efficacy in the treatment of many disorders. DehydraTECH™2.0 CBD is a patented capsule formulation that improves the bioabsorption of CBD. We sought to compare the effects of CBD and DehydraTECH™2.0 CBD ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Batinic, Ana, Sutlović, Davorka, Kuret, Sendi, Matana, Antonela, Kumric, Marko, Bozic, Josko, Dujic, Zeljko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223705/
https://www.ncbi.nlm.nih.gov/pubmed/37242428
http://dx.doi.org/10.3390/ph16050645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223705/
https://www.ncbi.nlm.nih.gov/pubmed/37242428
http://dx.doi.org/10.3390/ph16050645

Ejemplares similares